logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. The cost-effectiveness of screening for type 2 diabetes.

    Article - En anglais

    Context. - Type 2 diabetes mellitus is a common and serious disease in the United States, but one third of those affected are unaware they have it.

    Objective

    - To estimate the cost-effectiveness of early detection and treatment of type 2 diabetes.

    Design

    - A Monte Carlo computer simulation model was developed to estimate the lifetime costs and benefits of 1-time opportunistic screening (ie, performed during routine contact with the medical care system) for type 2 diabetes and to compare them with current clinical practice.

    Cost-effectiveness was estimated for all persons aged 25 years or older, for age-specific subgroups, and for African Americans.

    Data were obtained from clinical trials, epidemiologic studies, and population surveys, and a single-payer perspective was assumed.

    Costs and benefits are discounted at 3% and costs are expressed in 1995 US dollars.

    Setting

    - Single-payer health care system.

    Participants

    - Hypothetical cohort of 10000 persons with newly diagnosed diabetes from the general US population.

    Main Outcome Measures

    - Cost per additional life-year gained and cost per quality-adjusted life-year (QALY) gained.

    Results

    - The incremental cost of opportunistic screening among all persons aged 25 years or older is estimated at $236 449 per life-year gained and $56 649 per QALY gained.

    Screening is more cost-effective among younger people and among African Americans. (...)

    Mots-clés Pascal : Diabète non insulinodépendant, Dépistage, Précoce, Arbre décision, Exploration clinique, Diagnostic, Analyse coût efficacité, Homme, Etats Unis, Amérique du Nord, Amérique, Endocrinopathie, Economie santé

    Mots-clés Pascal anglais : Non insulin dependent diabetes, Medical screening, Early, Decision tree, Clinical investigation, Diagnosis, Cost efficiency analysis, Human, United States, North America, America, Endocrinopathy, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0019865

    Code Inist : 002B21E01A. Création : 31/05/1999.